OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(1.11) per share which missed the analyst consensus estimate of $(0.64) by 73.44 percent. This is a 6.72 percent increase over losses of $(1.19) per share from the same period last year.